CoChat

A European, multicentre, retrospective, non‐interventional study ( EU‐TREAT ) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes

Open access
Siegmund, Thorsten, Tentolouris, Nikolaos, Knudsen, Søren T., Lapolla, Annunziata, Prager, Rudolf, Phan, Tra‐Mi, Wolden, Michael L., Schultes, Bernd, for the EU‐TREAT study group · 2018 · Diabetes, Obesity and Metabolism
Cited by 44

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Aims: To evaluate the clinical effectiveness of switching to insulin degludec (IDeg) in insulin‐treated patients with either type 1 diabetes (T1DM) or type 2 diabetes (T2DM) under conditions of routine clinical care. Materials and Methods: This was a multicentre, retrospective, chart review study. In all patients, basal insulin was switched to IDeg at least 6 months before the start of data collection. Baseline was defined as the most recent recording during the 3‐month period before first prescription of IDeg. Values are presented as mean [95%CI]. Results: T1DM (n = 1717): HbA1c decreased by −2.2 [−2.6; −2.0] mmol/mol (−0.20 [−0.24; −0.17]%) at 6 months vs baseline ( P < .001). Rate ratio of overall (0.79 [0.69; 0.89]), non‐severe nocturnal (0.54 [0.42; 0.69]) and severe (0.15 [0.09; 0.24]) hypoglycaemia was significantly lower in the 6‐month post‐switch period vs the pre‐switch period ( P < .001 for all). Total daily insulin dose decreased by −4.88 [−5.52; −4.24] U (−11%) at 6 months vs baseline ( P < .001). T2DM (n = 833): HbA1c decreased by −5.6 [−6.3; −4.7] mmol/mol (−0.51 [−0.58; −0.43] %) at 6 months vs baseline ( P < .001). Rate ratio of overall (0.39 [0.27; 0.58], P < .001), non‐severe nocturnal (0.10 [0.06; 0.16], P < .001) and severe (0.075 [0.01; 0.43], P = .004) hypoglycaemia was significantly lower in the 6‐month post‐switch period vs the pre‐switch period. Total daily insulin dose decreased by −2.48 [−4.24; −0.71] U (−3%) at 6 months vs baseline ( P = .006). Clinical outcomes for T1DM and T2DM at 12 months were consistent with results at 6 months. Conclusions: This study demonstrates that switching patients to IDeg from other basal insulins improves glycaemic control and significantly reduces the risk of hypoglycaemia in routine clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13149

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 44

Metadata

Authors
Siegmund, T., Tentolouris, N., Knudsen, S. T., Lapolla, A., Prager, R., Phan, T., Wolden, M. L., Schultes, B., & for the EU‐TREAT study group
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2017-11-21
Volume
20
Issue
3
Pages
689-697
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2767832909
Cited by
44
References
11
FWCI
4.08
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A European, multicentre, retrospective, non‐interventional study ( EU‐TREAT ) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes. https://app.cochat.ai/papers/10.1111/dom.13149
The paper
Siegmund, T., Tentolouris, N., Knudsen, S. T., Lapolla, A., Prager, R., Phan, T., Wolden, M. L., Schultes, B., & for the EU‐TREAT study group. (2018). A European, multicentre, retrospective, non‐interventional study ( EU‐TREAT ) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13149

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.